The Specimen Core provides part of the infrastructure support for Projects 1 - 5 as well as for future pilot and developmental projects. It has been designed to meet the needs of these projects plus serve as a stand- alone resource for collaborative efforts with other SPOREs. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. Furthermore, the centralized management of the specimens will facilitate their distribution based upon the priorities defined by a panel of investigators familiar with all of our SPORE research endeavors. The operations of this Core group into 5 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases. 2. A development program to continually improve the quality and efficiency with which we obtain tissue samples and derivative products. 3. A prostate cancer xenograft maintenance, development and study program. 4. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e. PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources, and 5. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, ensure patient confidentiality and compliance with IRB requirements, and to interact with other prostate SPOREs. The performance of translational research mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core have decades of experience in recognizing these needs and providing such services not only to local investigators but to those who request specimens on a world-wide basis. For example, samples of specimens from our rapid autopsy program (e.g. prostate cancer bone metastases) and our LuCaP series of prostate cancer xenografts have been distributed internationally. In this renewal, such interactions with our own SPORE investigators, those collaborations with other SPORE investigators and collaborations with non- SPORE investigators will be a high priority. This will truly enhance the translational aspects of the NW Prostate Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-10
Application #
8330644
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-08-31
Budget Start
2011-09-08
Budget End
2012-08-31
Support Year
10
Fiscal Year
2011
Total Cost
$328,931
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53

Showing the most recent 10 out of 400 publications